Shield Therapeutics plc (LON:STX – Get Free Report)’s share price traded up 18.2% on Tuesday . The stock traded as high as GBX 3.58 ($0.04) and last traded at GBX 3.46 ($0.04). 7,009,878 shares changed hands during mid-day trading, an increase of 146% from the average session volume of 2,846,169 shares. The stock had previously closed at GBX 2.93 ($0.04).
Shield Therapeutics Trading Down 2.5 %
The business’s 50-day simple moving average is GBX 2.74 and its 200-day simple moving average is GBX 3.36. The company has a current ratio of 1.05, a quick ratio of 2.16 and a debt-to-equity ratio of 3,691.50. The company has a market cap of £29.36 million, a PE ratio of -93.85 and a beta of 1.42.
About Shield Therapeutics
Shield is a commercial-stage specialty pharmaceutical company that delivers Accrufer®/Feraccru® (ferric maltol), an innovative and differentiated pharmaceutical product, to address a significant unmet need for patients suffering from iron deficiency, with or without anemia. The Company has launched Accrufer® in the U.S.
Featured Articles
- Five stocks we like better than Shield Therapeutics
- Using the MarketBeat Stock Split Calculator
- 3 Reasons Micron Stock Is Deeply Undervalued Right Now
- Options Trading – Understanding Strike Price
- Inflation Persists, But So Do Stock Opportunities: Rally On
- 3 Warren Buffett Stocks to Buy Now
- Energy Transfer Fuels the Cloud: A Natural Gas Power Play
Receive News & Ratings for Shield Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Shield Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.
